Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18974619 | HYBRID FLU-CORONAVIRUS VACCINE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17997875 | DETECTION ASSAY FOR SARS-COV-2 VIRUS | Final Rejection | The Regents of the University of California |
| 17995850 | COMPOSITIONS, KITS, AND METHODS FOR ANTI-MICROBIAL SEROLOGY ASSAYS USING ANTI-HUMAN IMMUNOGLOBULIN ANTIBODY | Non-Final OA | Siemens Healthcare Diagnostics Inc. |
| 18552406 | CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18017726 | IMPROVED AAV-MEDIATED X-LINKED RETINOSCHISIS THERAPIES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17996608 | SARS-COV-2 VACCINES | Non-Final OA | NEC LABORATORIES EUROPE GMBH |
| 17312916 | HIV SEROSIGNATURES FOR CROSS-SECTIONAL INCIDENCE ESTIMATION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17393742 | COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | Final Rejection | Roche Molecular Systems, Inc. |
| 18559272 | IMMUOGENIC COMPOSITIONS OF MUTANT SARS-COV-2 N PROTEIN AND GENE AND METHODS OF USE THEREOF | Non-Final OA | King Abdullah University of Science and Technology |
| 18356448 | BACTERIOPHAGE INFECTING DIABETES-INDUCING BACTERIUM AND USE THEREOF | Non-Final OA | AJINOMOTO CO., INC. |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy